Abbott Laboratories

New York Stock Exchange
Back to all articles
Somewhat Bullish +45

The FDA Just Gave Abbott a Diabetes First. Is Its Beaten-Down Stock Ready to Wake Up? - 24/7 Wall St.

AI-generated analysis

🏥 Abbott received FDA De Novo authorization for the Libre Duo, becoming the first wearable cleared to continuously monitor both glucose and ketone levels.

📉 The stock has declined 11.29% over the past year, trading at a forward P/E of 21x against an analyst price target of $120.20.

👥 The new device targets an existing ecosystem of over 8 million users with plans for a U.S. launch later in 2026 for patients ages 2 and older.

💰 Q2 continuous glucose monitoring (CGM) sales reached $2.188 billion, representing a 9.5% comparable growth rate.

🤝 Planned integrations with insulin pumps from Beta Bionics, Sequel, Insulet, Tandem, and MiniMed are critical for workflow adoption but are not yet live.

📈 CEO Robert Ford indicated that reimbursement expansion could drastically accelerate growth, with potential U.S. Type 2 coverage reaching around 10 million Medicare beneficiaries.

⚖️ Competitor Dexcom shares have rallied 34% year-to-date, creating a performance gap that Abbott aims to close through the Libre Duo launch.

📅 The company plans to provide adjusted EPS guidance of $1.38 to $1.46 in the upcoming Q3 earnings report.

🔬 Ketone detection capability allows for early warning of diabetic ketoacidosis, which can develop within hours, offering a genuine clinical distinction.

Bullish Signals
  • Abbott Laboratories secured the first FDA clearance for a wearable device that simultaneously tracks glucose and ketones, addressing a critical safety need for diabetic ketoacidosis prevention.
  • The company enters the market with an established ecosystem of over 8 million existing users, providing a strong foundation for rapid adoption of the new Libre Duo technology.
  • Q2 CGM sales demonstrated robust growth of 9.5% to reach $2.188 billion, indicating sustained demand in the continuous monitoring sector.
  • CEO Robert Ford highlighted that reimbursement expansion could drastically accelerate growth, with potential coverage reaching approximately 10 million Medicare beneficiaries.
Risk Factors
  • The stock has underperformed significantly compared to rival Dexcom, which rallied 34% year-to-date while Abbott declined 11% over the same period.
  • Planned integrations with insulin pumps from major partners like Tandem and Insulet are not yet live, limiting the device's current utility as a differentiator in clinical workflows.
  • The regulatory milestone precedes immediate revenue impact, requiring successful commercial execution and reimbursement approvals to realize full value.
Full Analysis
Abbott Laboratories achieved a significant regulatory milestone with the FDA granting De Novo authorization for its Libre Duo, becoming the first company to clear a wearable device capable of continuously monitoring both glucose and ketone levels. This innovation targets an existing ecosystem of over 8 million users and aims to provide early warnings for diabetic ketoacidosis, a critical safety feature that distinguishes it from competitors. Despite this breakthrough, Abbott's stock has underperformed relative to rival Dexcom, which rallied 34% year-to-date while Abbott declined 11% over the same period. The company trades at a forward P/E of 21x with analysts targeting a price of $120.20, suggesting potential for re-rating if the new device drives substantial revenue growth and market share expansion. CEO Robert Ford highlighted that reimbursement expansion is crucial for accelerating growth, noting that potential U.S. Type 2 coverage could reach approximately 10 million Medicare beneficiaries. However, the full commercial impact of Libre Duo depends on future integrations with insulin pumps from major partners like Tandem and Insulet, which are not yet live. Investors should monitor the upcoming Q3 earnings report for adjusted EPS guidance between $1.38 and $1.46, as well as any announcements regarding broader CMS coverage for Type 2 diabetes. These events are expected to be key catalysts in converting Abbott's first-mover status into durable earnings power and validating its beaten-down valuation.